USP7抑制剂P22077对Ang II诱导高血压小鼠心脏肥大的抑制作用研究
Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice
Gu Yu-Hui, Ren Kai-Wen, Wang Yu, Wang Shi-Hao, Yu Xiao-Hong, Xu Li-Wen, Li Hui-Hua, Bi Hai-Lian
Journal:Frontiers in Pharmacology
IF:5.99
DOI:10.3389/fphar.2022.1021361
PMID:36386139
Published:2022-10-25
research field:肿瘤学分子生物学药理学
Abstract
Hypertension is one of the common causes of pathological cardiac hypertrophy and a major risk for morbidity and mortality of cardiovascular diseases worldwide. Ubiquitin-Specific Protease 7 (USP7), the first identified deubiquitinating enzymes, participated in a variety of biological processes, such as cell proliferation, DNA damage response, tumourigenesis, and apoptosis. However, its role and mechanism in cardiac remodeling remain unclear. Here, our data indicated that USP7 expression was increased during Ang II-induced cardiac hypertrophy and remodeling in mice and humans with heart failure, while the administration of its inhibitor p22077 attenuated cardiac hypertrophy, cardiac fibrosis, inflammation, and oxidase stress. Mechanistically, the administration of p22077 inhibited the multiple signaling pathways, including AKT/ERK, TGF-β/SMAD2/Collagen I/Collagen III, NF-κB/NLRP3, and NAPDH oxidases (NOX2 and NOX4). Taken together, these findings demonstrate that USP7 may be a new therapeutic target for hypertrophic remodeling and HF.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


